← All trials
NCT04290208
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 22, 2019
- Primary completion
- Jun 23, 2020
- Completion date
- Jun 23, 2020
- First posted
- Feb 28, 2020
- Last posted
- Feb 28, 2020
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Main Line HealthLead sponsor
- Sharpe-Strumia Research FoundationCollaborator
- Bryn Mawr HospitalOverall official - principal investigator
- Main Line HealthReponsible party - principal investigator
- Main Line HealthOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.